[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632891":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":11,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":11,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":11,"overallStatus":62,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CM512","EXPERIMENTAL",null,[13],"Biological: CM512",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Administered subcutaneous injection",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Qian Jia","CONTACT","028-88610620","clinicaltrial@keymedbio.com",[26],{"facility":27,"status":11,"city":28,"state":11,"zip":11,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Beijing Tong-Ren hospital","Beijing","China","CN",{"type":32,"coordinates":33},"Point",[34,35],116.39723,39.9075,{"lat":35,"lon":34},[38],{"name":39,"role":22,"phone":40,"phoneExt":11,"email":24},"Luo Zhang","010-58268486-8009",{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100632891","phase-2-a-study-of-cm512-in-patients-with-chronic-rhinosinusitis-with-nasal-polyposis-nezha-2-100632891",false,"NCT07519577","A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）","An Open-Label, Single-Arm, Multicenter, Extension Study to Evaluate the Safety and Efficacy of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis","Inclusion Criteria:\n\n* Participated in the clinical study of CM512 in patients with Chronic Rhinosinusitis with Nasal Polyposis (Study No. of CM512-102101) .\n\nExclusion Criteria:\n\n* Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for biologic therapy\u002Fsystemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity.\n* Administration of a live attenuated vaccine within 30 days prior to baseline or planning to receive one during the study period.","ALL","18 Years","75 Years",{"count":54,"type":55},120,"ESTIMATED","INTERVENTIONAL",[58],"PHASE2","This is an open-label, single-arm, multicenter, extension study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis",[61],"Chronic Rhinosinusitis With Nasal Polyposis","NOT_YET_RECRUITING","2026-06-26",{"date":65,"type":66},"2026-06-30","ACTUAL",{"date":68,"type":55},"2026-05-31",{"date":70,"type":55},"2028-05-31",{"name":5,"class":6},1]